Adult Growth Hormone Deficiency, Growth Hormone Disorder
Conditions
Brief summary
This study is conducted in Europe. The aim of this study is to extract data from the French National Registry holding information about patients having initiated growth hormone therapy with the objective to describe patients receiving growth hormone therapy, assess efficacy and safety of somatropin (Norditropin® SimpleXx®) and evaluate treatment compliance.
Interventions
DRUGsomatropin
Data are extracted from the French National Registry l'Observatoire National des Prescriptions et Consommations de Médicaments to where physicians report data about growth hormone treatment
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Adult with growth hormone deficiency * Treated with Norditropin® SimpleXx (somatropin)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight | Once a year for 5 years |
| Body composition | Once a year for 5 years |
| Waist:Hip Ratio | Once a year for 5 years |
| Body mass index (BMI) | Once a year for 5 years |
Secondary
| Measure | Time frame |
|---|---|
| Lipids: Total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and triglycerides | Once a year for 5 years |
| Dose prescribed | Once a year for 5 years |
| IGF-1 (Insulin-like growth factor 1) concentration | Once a year for 5 years |
Countries
France
Outcome results
None listed